Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort | Zendy

Linda Wittkop | Zendy; Dominique Breilh | Zendy; D. Da Silva | Zendy; P. Duffau | Zendy; P. Mercié | Zendy; Isabelle RaymondLetron | Zendy; Guerric Anies | Zendy; Heloísa Junqueira Fleury | Zendy; M C Saux | Zendy; François Dabis | Zendy; Catherine Fagard | Zendy; Rodolphe Thiébaut | Zendy; Bernard Masquelier | Zendy; I. Pellegrin | Zendy

Open Access

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort

Author(s) -

Linda Wittkop,

Dominique Breilh,

D. Da Silva,

P. Duffau,

P. Mercié,

Isabelle RaymondLetron,

Guerric Anies,

Heloísa Junqueira Fleury,

M C Saux,

François Dabis,

Catherine Fagard,

Rodolphe Thiébaut,

Bernard Masquelier,

I. Pellegrin

Publication year - 2009

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkp114

Subject(s) - raltegravir , medicine , interquartile range , regimen , cohort , viral load , gastroenterology , cohort study , human immunodeficiency virus (hiv) , immunology , antiretroviral therapy

The efficacy of raltegravir plus optimized background therapy (OBT) has been demonstrated for antiretroviral (ARV)-experienced HIV-1-infected patients in randomized clinical trials. We studied viro-immunological response, pharmacokinetic parameters and genotypic test results in an observational cohort of multiple ARV class-experienced patients starting a raltegravir-based regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research